RAD51 135G>C modifies breast cancer risk among BRCA2 mutation carriers: Results from a combined analysis of 19 studies
Citation:
Antonis C. Antoniou, Olga M. Sinilnikova, Jacques Simard, Melanie Leone, Martine Dumont, Susan L. Neuhausen, Jeffery P. Struewing, Dominique Stoppa-Lyonnet, Laure Barjhoux, David J. Hughes, Isabelle Coupier, Muriel Belotti, Christine Lasset, Valerie Bonadona, Yves-Jean Bignon, Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers Study (GEMO), Timothy R. Rebbeck, Theresa Wagner, Henry T. Lynch, Susan M. Domchek, Katherine L. Nathanson, Judy E. Garber, Jeffrey Weitzel, Steven A. Narod, Gail Tomlinson, Olufunmilayo I. Olopade, Andrew Godwin, Claudine Isaacs, Anna Jakubowska, Jan Lubinski, Jacek Gronwald, Bohdan Gorski, Tomasz Byrski, Tomasz Huzarski, Susan Peock, Margaret Cook, Caroline Baynes, Alexandra Murray, Mark Rogers, Peter A. Daly, Huw Dorkins, Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE), Rita K. Schmutzler, Beatrix Versmold, Christoph Engel, Alfons Meindl, Norbert Arnold, Dieter Niederacher, Helmut Deissler, German Consortium for Hereditary Breast and Ovarian Cancer (GCHBOC), Amanda B. Spurdle, Xiaoqing Chen, Nicola Waddell, Nicole Cloonan, The Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab), Tomas Kirchhoff, Kenneth Offit, Eitan Friedman, Bella Kaufmann, Yael Laitman, Gilli Galore, Gad Rennert, Flavio Lejbkowicz, Leon Raskin, Irene L. Andrulis, Eduard Ilyushik, Hilmi Ozcelik, Peter Devilee, Maaike P. G. Vreeswijk, Mark H. Greene, Sheila A. Prindiville, Ana Osorio, Javier Ben?'tez, Michal Zikan, Csilla I. Szabo, Outi Kilpivaara, Heli Nevanlinna, Ute Hamann, Francine Durocher, Adalgeir Arason, Fergus J. Couch, Douglas F. Easton, and Georgia Chenevix-Trench, on behalf of the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) `RAD51 135G>C modifies breast cancer risk among BRCA2 mutation carriers: Results from a combined analysis of 19 studies? in American Journal of Human Genetics, 81, 2007, pp 1186 ? 1200Download Item:
Abstract:
Though much progress has been made in understanding the role of two major high-risk breast cancer (BC) susceptibility genes, BRCA1 and BRCA2, it remains unclear what causes the observed variation in risk between mutation carriers. This marked variability in individual cancer risk both between and within BRCA1 and BRCA2 mutation carrier families may be partly explained by modifier genes that influence mutation penetrance. Defining these modifiers should help refine individual cancer risk estimates and is also expected to be an efficient method to identify further BC susceptibility alleles in general. This approach is predicated on the concept that variants in genes that are low to moderate penetrance predisposition genes are likely to have a larger risk modification effect in BRCA1/2 mutation carriers. Association studies are usually used to assess the influence of variants in biologically plausible candidate loci on the penetrance of BRCA1/2 mutations (i.e., differences in age of onset or tissue-specificity of disease). Several such modifier loci, including the genes AIB1 and AR involved in hormone metabolism, and the RAD51 gene acting in DNA repair, have been proposed in the literature. A consortium of laboratories (CIMBA) has recently confirmed the RAD51 135 G/C variant as a BC risk modifier in BRCA2 mutation carriers, though not in BRCA1 carriers. This review describes molecular epidemiological efforts to evaluate the potential influence of polymorphic variants in candidate modifier genes on the risk of BC conferred by the BRCA1 and BRCA2 genes.
Author's Homepage:
http://people.tcd.ie/hughesd4Description:
PUBLISHED
Author: HUGHES, DAVID
Publisher:
The American Society of Human GeneticsType of material:
Journal ArticleCollections
Series/Report no:
American Journal of Human Genetics81
Availability:
Full text availableKeywords:
oncology, human geneticsMetadata
Show full item recordLicences: